Statement of Chester “Chip” Davis Jr., President and CEO of the Association for Accessible Medicines on the Nomination of Dr. Scott Gottlieb as Commissioner of Food and Drug Administration.
(March 11, 2017) WASHINGTON, DC – “President Donald Trump’s nomination of Dr. Scott Gottlieb to lead the Food and Drug Administration signals he is serious about increasing access to safe, effective and affordable medicines for Americans while taking a market based, competitive approach towards lowering drug costs. Dr. Gottlieb is one of the most formidable thought leaders in the medical field and makes an excellent choice to lead the agency responsible for ensuring the public health of the millions of patients FDA serves.
“Dr. Gottlieb has advocated for effectively addressing the backlog of generic drug applications pending at FDA and ensuring that quality products are approved at their earliest possible date; thus, increasing competition to lower costs of drugs and biologics for millions of Americans. We stand ready to work with the President, Dr. Gottlieb and his entire team to ensure that generic medicines continue to keep lifesaving treatments within reach of all Americans. We strongly urge the Senate to move forward with his confirmation in order to begin addressing the important task of lowering prescription drug costs for Americans.”
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 89 percent of prescriptions dispensed in the U.S. but only 27 percent of total drug spending. Additional information is available at www.accessiblemeds.org.